Samsung Biologics Co Ltd (207940) — Cash Flow-to-Debt Ratio
Samsung Biologics Co Ltd (207940) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of ₩619.30 Billion could theoretically repay 0% of its total liabilities (₩6.16 Trillion) in one year. See Samsung Biologics Co Ltd (207940) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Samsung Biologics Co Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Samsung Biologics Co Ltd across 11 annual periods. Also explore how fast is Samsung Biologics Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Samsung Biologics Co Ltd (2014–2024)
Year-by-year debt coverage analysis for Samsung Biologics Co Ltd. For market capitalisation and broader financial context, see 207940 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.26x | ₩1.66 Trillion | ₩6.43 Trillion | ▼ -3.8% |
| 2023 | 0.27x | ₩1.67 Trillion | ₩6.22 Trillion | ▲ +113.7% |
| 2022 | 0.13x | ₩953.05 Billion | ₩7.60 Trillion | ▼ -17.8% |
| 2021 | 0.15x | ₩454.60 Billion | ₩2.98 Trillion | ▲ +37.8% |
| 2020 | 0.11x | ₩202.09 Billion | ₩1.83 Trillion | ▲ +1597.8% |
| 2019 | 0.01x | ₩10.15 Billion | ₩1.56 Trillion | ▲ +136.0% |
| 2018 | -0.02x | ₩-33.02 Billion | ₩1.82 Trillion | ▼ -138.7% |
| 2017 | 0.05x | ₩149.82 Billion | ₩3.21 Trillion | ▲ +357.3% |
| 2016 | -0.02x | ₩-62.66 Billion | ₩3.45 Trillion | ▲ +78.2% |
| 2015 | -0.08x | ₩-265.51 Billion | ₩3.19 Trillion | ▲ +44.2% |
| 2014 | -0.15x | ₩-108.30 Billion | ₩724.97 Billion | — |